934426-22-9

Basic information

• Product Name: 2-aMino-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)benzonitrile
• Synonyms: 2-aMino-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)benzonitrile
• CAS NO: 934426-22-9
• Molecular Formula: C₁₃H₁₇BN₂O₂
• Molecular Weight: 244.09728
• Mol File: 934426-22-9.mol
• Article Data: 16

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-aMino-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-aMino-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)benzonitrile(934426-22-9)
• EPA Substance Registry System: 2-aMino-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)benzonitrile(934426-22-9)

Safety Data

• Hazardous Substances Data: 934426-22-9(Hazardous Substances Data)

Usage

Common usage

Building block in organic synthesis and medicinal chemistry

Derivative

Derived from benzonitrile

Structural feature

Contains a boron atom linked to a tetramethyl-dioxaborolane group

Potential applications

Pharmaceuticals and agrochemicals development
Preparation of fluorescent dyes
Materials for organic electronic devices
Catalysis
Reagent in organic reactions

Upstream product

• 132131-24-9 5-iodoanthranilonitrile 
• 73183-34-3 bis(pinacol)diborane 
• 1885-29-6 anthranilic acid nitrile 
• 5922-60-1 2-amino-5-chlorobenzonitrile 
• 39263-32-6 2-amino-5-bromobenzonitrile 

Downstream Products

• 934426-24-1 N'-[2-cyano-4-(4,4,5,5-tetramethyl-[1.3.2]dioxaborolan-2-yl)-phenyl]-N,N-dimethyl-formamidine 
• 1292317-50-0 2-amino-5-(2-chloropyrimidin-4-yl)benzonitrile 
• 1443283-34-8 2-amino-5-[1-methyl-3-phenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 
• 1443283-46-2 2-amino-5-[2-methyl-3-phenyl-4-(trifluoromethyl)-2H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 
• 1443283-73-5 2-amino-5-[1-methyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 
• 1443283-71-3 2-amino-5-[2-methyl-4-(trifluoromethyl)-2H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 
• 1443283-51-9 2-amino-5-[4-(difluoromethyl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 
• 1279842-22-6 2-amino-5-[4-(difluoromethyl)-2-methyl-2H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 
• 1443284-00-1 2-amino-5-[4-(difluoromethyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 
• 1443283-55-3 2-amino-5-[4-(difluoromethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 
• 1443284-09-0 2-amino-5-[4-(difluoromethyl)-3-(pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 
• 1443283-77-9 2-amino-5-[4-(difluoromethyl)-3-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 

Relevant articles and documents

CANCER TREATMENTS TARGETING CANCER STEM CELLS

Disclosed are compounds, methods, compositions, uses, and kits that allow for treating cancer. In some embodiments, the compounds are used to treat diseases or disorders. The compounds may treat cancer by targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, lymphoma, liver cancer, endometrial cancer, leukemia, or multiple myeloma. Disclosed are compounds, methods, compositions, uses, and kits that may be used in regenerative medicine. The compounds utilized in the disclosure are of Formula (0) and (I).

AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF

The present invention aims to provide a compound that: has an excellent cytotoxic action on cancer cells, excellent induction of BET protein degradation in cancer cells, and an excellent binding-inhibiting action on BET protein and acetylated histone; and is effective as an anti-cancer agent, a BET protein degradation-inducing agent, or a BET protein inhibiting agent. A compound indicated in general formula (I) or a pharmacologically acceptable salt thereof. {In the formula, each symbol is as outlined in the Description.}

NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE

Disclosed are a nitrogenous heterocyclic compound, intermediates, a preparation method, a composition and use thereof. The nitrogenous heterocyclic compound in the present invention is as shown in formula I. The compound has a high inhibitory activity towards ErbB2 tyrosine kinase and a relatively good inhibitory activity towards human breast cancer BT-474 and human gastric cancer cell NCI-N87 which express ErbB2 at a high level, and at the same time has a relatively weak inhibitory activity towards EGFR kinase. Namely, the compound is a highly selective small-molecule inhibitor targeted at ErbB2, and hence it has a high degree of safety, and can effectively enlarge the safety window in the process of taking the drug.